ResMed Inc. (RMD)
RMD · Health Care · 
United States
ResMed Inc. (RMD) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 0.54%. Anyone who holds an ETF containing ResMed also has an indirect stake in the company.
Data and Charts: ResMed
Key Data for ResMed
ResMed Stock Price Chart
The ResMed chart shows daily closing prices and is set to the current year by default. The stock is down 4.5% year to date and down 8.8% over twelve months. The last recorded close on October 30, 2026, was $229.94, at 51% of the 52-week range.
Price series from our database since Aug 12, 2024, 558 daily values.
ResMed Stock Performance
| Year to date | -4.5% | 1 year | -8.8% |
|---|---|---|---|
| 1 month | +4.0% | 3 months | +9.0% |
| Calendar year 2025 | +5.3% |
Measured in euros, ResMed is up 0.4% year to date and down 5.8% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: ResMed
What ETF Is ResMed In?
ResMed has above-average ETF coverage and is held by 21 of the 104 ETFs we track, which together follow 10 indices. That puts the stock in more ETFs than 82.8% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 0.54% | €5.43 |
| XDWH | MSCI World Health Care | 0.40% | €4.04 |
| SPFS | MSCI World Health Care | 0.40% | €4.02 |
| XDEW | S&P 500 Equal Weight | 0.22% | €2.24 |
| XDEQ | MSCI World Quality | 0.07% | €0.69 |
| SPYL / SPY5 | S&P 500 | 0.06% | €0.57 |
| SPYI / SPSA | MSCI ACWI IMI | 0.06% | €0.56 |
| XD9U / XD9D | MSCI USA | 0.05% | €0.55 |
| SXR8 | S&P 500 | 0.05% | €0.50 |
| XDWD / XDWL | MSCI World | 0.04% | €0.40 |
| EUNL | MSCI World | 0.04% | €0.40 |
| SPYY | MSCI ACWI | 0.04% | €0.38 |
| SWWD | MSCI World | 0.04% | €0.38 |
| SPPW | MSCI World | 0.04% | €0.38 |
| WIMI | MSCI World IMI | 0.04% | €0.36 |
| IUSQ | MSCI ACWI | 0.03% | €0.30 |
The last column shows how much of €1,000 in one of these funds goes to ResMed, based on each fund's latest holdings list.
US-listed ETFs holding ResMed (weight per latest SEC filing): VUG 0.10%, IVV 0.04%, SPY 0.04%, VOO 0.04%, VTI 0.04%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
ResMed Weight in iShares Core MSCI World (EUNL) Since 2019
In iShares Core MSCI World (EUNL), ResMed had a weight of 0.04% on Sep 30, 2019 and 0.04% on Oct 30, 2026. The fund tracks the MSCI World. Its share peaked at 0.07% on Mar 31, 2020. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much ResMed overlaps with the rest of a portfolio.
Which Tracked Investors Hold ResMed?
ResMed is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds ResMed increased its position.
| Investor | Shares | Value | Quarter |
|---|---|---|---|
| Bridgewater Associates | 67,381 | $13M | increased by 28,144 |
As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.
What ResMed Executives and Directors Traded Recently
| Date | Person | Type | Shares | Price |
|---|---|---|---|---|
| Oct 23, 2026 | Rider Michael J Officer, Global General Counsel | Sell (plan) | 400 | $255.00 |
| Oct 7, 2026 | Farrell Michael J. Director, Officer, Chairman and CEO | Sell (plan) | 4,991 | $226.33 |
The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded.
“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32.
Stocks With ETF Exposure Similar to ResMed
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| ResMed | – | – | -8.8% | 28.8% | 26.9% | +9.9% |
 Waters Corporation | 21 | – | +34.9% | 37.1% | 20.3% | +7.0% |
| Zoetis | 21 | – | -44.7% | 31.4% | 28.2% | +2.3% |
 Eli Lilly and Company | 21 | – | +67.9% | 38.0% | 31.7% | +44.7% |
 Boston Scientific Corporation | 20 | – | -58.3% | 30.9% | 14.4% | +19.9% |
 Danaher Corporation | 20 | – | +8.0% | 30.5% | 14.7% | +2.9% |
 Thermo Fisher Scientific | 20 | – | +25.3% | 29.8% | 15.0% | +3.9% |
| Agilent Technologies | 20 | – | +22.0% | 31.4% | 18.8% | +6.7% |
 IQVIA Holdings Inc | 20 | – | +23.5% | 38.6% | 8.3% | +5.9% |
These stocks reach a portfolio through largely the same funds as ResMed. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: ResMed
ResMed Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Jun 30, 2026).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Jun 2023 | 4.2 | 0.9 | 21.3% |
| FY ended Jun 2024 | 4.7 | 1.0 | 21.8% |
| FY ended Jun 2025 | 5.1 | 1.4 | 27.2% |
| FY ended Jun 2026 | 5.7 | 1.5 | 26.9% |
Technical Analysis: ResMed
ResMed Risk Metrics
The close on Oct 30, 2026, was 21.7% below the highest close since Aug 12, 2024. That high was reached on Aug 22, 2025. When the S&P 500 rose or fell 1%, ResMed moved 0.47% on average in the same direction (past 252 trading days). The correlation of 0.20, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of ResMed.
What ResMed Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| IDEXX Laboratories Inc. | +0.64 | |
| Stryker Corporation | +0.56 | |
| STERIS plc | +0.55 | |
| News Corporation Class A | +0.54 | |
| News Corporation Class B | +0.54 | |
| Trade Desk Inc. Class A | +0.53 | |
| MasTec Inc. | -0.43 | |
| SOPH | -0.41 | |
| Brent crude oil | -0.40 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
